ENCell Presents the Phase 1 Clinical Trial Results of EN001 for Charcot-Marie-Tooth Disease at the PNS conference
ENCell presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell therapy (EN001) for Charcot-Marie-Tooth disease type 1A (CMT1A) at the Peripheral Nerve Society (PNS) annual meeting in Montreal on June 23, 2024.
The trial results, which were selected for oral presentation at the PNS meeting, showed no dose-limiting toxicity, serious adverse events, or infusion-related responses among participants, thereby confirming the safety of EN001. Additionally, exploratory efficacy evaluations revealed significant improvements. The Charcot-Marie-Tooth Neuropathy Score version 2 decreased by an average of 2.89 points (p=0.0039) after 16 weeks, with the high-dose group showing a more pronounced reduction of 3.50 points (p=0.0313).
Further analysis indicated that patients receiving the high dose experienced clinical improvements in disease severity, with some moving from severe to moderate or from moderate to mild categories. Specific sensory and motor function tests also showed marked improvements, with the high-dose group. Enhancements in the 10 Meter Walking Test, Functional Disability Scale, Overall Neuropathy Limitation Score leg scale, and nerve conduction studies were also observed.
An ENCell spokesperson highlighted the significance of presenting these promising clinical results at a prestigious conference, emphasizing the company's dedication to developing new treatment options for CMT patients, who currently lack approved therapies.
Professor Byung-Ok Choi, leading the clinical trial, expressed optimism, stating, “These results provide hope to CMT1A patients, a group affected by a rare disease without existing treatments.”
ENCell is planning to conduct repeat-administration clinical trial at SMC.
Website: http://www.encellinc.com/
Contact
ENCell Co., Ltd.
Choongseob Oh
Send Email
This news is a press release provided by ENCell Co., Ltd..
